Você procurou por: trombembooliliste (Estoniano - Inglês)

trombembooliliste juhtude kirjeldus, sh esinemise määrad kliinilistes uuringutes
description of thromboembolic events including incidence rates from clinical trials

conbrizat ei ole soovitatav kasutada naistel, kellel on suurenenud venoossete trombembooliliste nähtude risk.
use of conbriza is not recommended in women at an increased risk for venous thromboembolic events.

trombembooliliste kõrvaltoimete riskiga patsientidel tuleb ivig tooteid manustada minimaalse praktilise infusioonikiirusega ja annuses.
in patients at risk for thromboembolic adverse reactions, ivig products should be administered at the minimum rate of infusion and dose practicable.

sealjuures tuleb silmas pidada, et ka rasedus ja ohss ise kujutavad endast trombembooliliste nähtude riskifaktorit.
it should be noted however that pregnancy itself as well as ohss also carry an increased risk of thrombo-embolic events.

sealjuures tuleb silmas pidada, et raseduse ja ohss-iga iseenesest kaasneb trombembooliliste nähtude risk.
it should be noted however that pregnancy itself as well as ohss also carry an increased risk of thromboembolic events.

ix faktori preparaatide manustamise järel esineb potentsiaalne trombembooliliste episoodide risk, mis on madala puhtusastmega preparaatide korral suurem.
there is a potential risk of thromboembolic episodes following the administration of factor ix products, with a higher risk for low purity preparations.

cox-2 inhibiitorid ei asenda atsetüülsalitsüülhapet kardiovaskulaarsete trombembooliliste haiguste profülaktikas, sest neil puudub toime trombotsüütide agregatsioonile.
cox-2 inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects.

selektiivsed cox-2 inhibiitorid ei asenda atsetüülsalitsüülhapet kardiovaskulaarsete trombembooliliste haiguste profülaktikas, sest neil puudub toime trombotsüütide agregatsioonile.
cox-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effect.

naistel, kellel on trombembooliliste nähtude üldiselt tuntud riskifaktoreid kas isiklikus või perekonna anamneesis, võib ravi gonadotropiinidega riski veelgi suurendada.
5 in women with generally recognised risk factors for thrombo-embolic events, such as personal or family history, treatment with gonadotrophins may further increase the risk.

trombemboolilised sündmused. vwd-ga patsientidel, eriti teadaolevate kliiniliste või laboratoorsete riskiteguritega patsientidel, esineb trombembooliliste sündmuste tekkerisk.
thromboembolic events: in patients with vwd, there is a risk of occurrence of thromboembolic events, particularly in patients with known clinical or laboratory risk factors.

64 fataalsete trombembooliliste tüsistusjuhtude arv võrreldes platseebot saavate patsientidega suurem patsientidel, kes said alfaepoetiini (vt lõik 5. 1).
in that study the incidence of fatal thromboembolic events was higher in patients receiving epoetin alfa than in those receiving placebo (see section 5.1).

36 kellel on suurenenud trombembooliliste tüsistuste oht, nt seoses rasvumisega või anamneesis oleva trombemboolilise episoodiga (nt süvaveenitromboos või kopsuarteri trombemboolia).
an investigational study (best study) in women with metastatic breast cancer was designed to determine whether epoetin alfa treatment that extended beyond the correction of anaemia could improve treatment outcomes.

kõrge trombembooliliste tüsistuste riskiga patsientidel peab ravi jätkama minimaalselt 30 päeva kuni maksimaalselt 45 päeva jooksul (vt lõigud 4.4 ja 5.1).
treatment should be continued for a minimum of 30 days and up to a maximum of 45 days in patients at high risk of thromboembolic complications (see sections 4.4 and 5.1).

meta-analüüs näitas järjekindalt inimese rekombinantset erütropoetiini saavatel vähihaigetel trombembooliliste juhtude esinemise riski suhtelist tõusu (vt lõik 4.4).
meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).

fviii sisaldavaid vwf- ravimeid saavatel patsientidel võivad pikaajalised liigsed fviii:c plasmatasemed suurendada trombembooliliste sündmuste tekkeriski (vt ka lõik 4.4).
in patients receiving fviii-containing vwf products, sustained excessive fviii:c plasma levels may increase the risk of thromboembolic events (see also section 4.4).

esa-sid saavatel patsientidel on täheldatud trombembooliliste tüsistuste (thrombotic vascular events, tve) esinemissageduse suurenemist (vt lõik 4.8).
an increased incidence of thrombotic vascular events (tves) has been observed in patients receiving esas (see section 4.8).